Tilray Brands (TLRY) Non-Current Assets (2017 - 2026)
Tilray Brands (TLRY) posted Non-Current Assets of $1.4 billion for Q1 2026, down 0.97% on a QoQ basis from $1.4 billion in Q4 2025.
Tilray Brands (TLRY) Non-Current Assets (2017 - 2026) Analysis & Trends
Tilray Brands' Non-Current Assets history runs 10 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- Quarterly Non-Current Assets changed N/A year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $5.5 billion (down 48.01% YoY) and the FY2025 annual result came in at $1.4 billion, down 60.9% from the prior year.
- Non-Current Assets was $1.4 billion for Q1 2026 at Tilray Brands, down from $1.4 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $5.1 billion in Q1 2022 and bottomed at $1.4 billion in Q1 2026.
- A 5-year average of $3.3 billion and a median of $3.6 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets advanced 0.28% — and 2025, when it sank 60.93%.
- Tilray Brands' Non-Current Assets stood at $4.7 billion in 2022, then fell by 20.84% to $3.7 billion in 2023, then decreased by 5.53% to $3.5 billion in 2024, then plunged by 60.7% to $1.4 billion in 2025, then retreated by 0.97% to $1.4 billion in 2026.
- Business Quant data shows TLRY's Non-Current Assets at $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 1.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.36 Bn |
| Nov 30, 2025 | 1.37 Bn |
| Aug 31, 2025 | 1.38 Bn |
| May 31, 2025 | 1.39 Bn |
| Nov 30, 2024 | 3.48 Bn |
| Aug 31, 2024 | 3.54 Bn |
| May 31, 2024 | 3.54 Bn |
| Feb 29, 2024 | 3.58 Bn |
| Nov 30, 2023 | 3.69 Bn |
| Aug 31, 2023 | 3.57 Bn |
| May 31, 2023 | 3.53 Bn |
| Feb 28, 2023 | 3.62 Bn |
| Nov 30, 2022 | 4.66 Bn |
| Aug 31, 2022 | 4.68 Bn |
| May 31, 2022 | 4.65 Bn |
| Feb 28, 2022 | 5.12 Bn |
| Nov 30, 2021 | 5.06 Bn |
| Aug 31, 2021 | 5.14 Bn |
| May 31, 2021 | 5.14 Bn |
| May 31, 2020 | 1.16 Bn |